NEW YORK (GenomeWeb News) – Mizuho Securities today upgraded Waters' stock to Buy from Neutral, citing the firm's exposure to the pharma industry, its presence in emerging markets, and its "strong" product cycle.

Mizuho also increased the price target on Waters' stock to $92 from $84. The investment firm lowered full-year 2012 revenue estimates to $1.89 billion from $1.91 billion, while maintaining an EPS estimate of $5.10.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."